ATA Inc. (ATAI)
ATAI Price and Sentiment
ATAI Latest news
Their clinical programs and research-enabling technologies both surpass the competition.
atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change2021-10-19 07:00
atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health care atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health care
Atai Life Sciences (NASDAQ:ATAI), a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix. PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression and other mental health indications.
Atai Life Sciences NV (NASDAQ: ATAI) has launched PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression (TRD) and other mental health indications.
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx's Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data2021-09-15 08:10
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has entered into an amended and restated loan agreement (“Loan Agreement”) with strategic partner IntelGenx Technologies Corp. (“IntelGenx”) to support IntelGenx's conditionally approved graduation from the TSX Venture Exchange to the Toronto Stock Exchange (“TSX”). Completion of the uplisting and the commencement of trading of IntelGenx's common shares, 8% convertible debentures with a maturity date of June 30, 2022, and share purchase warrants expiring on February 11, 2023 is subject to the satisfaction by IntelGenx of all of the final conditions of listing.
Perception Neuroscience, an Atai Life Sciences (NASDAQ:ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate. The study will evaluate the safety and efficacy of a proprietary formulation of arketamine that could have a similar therapeutic action to ketamine in the treatment of depression, with less dissociative effects.
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression2021-09-14 08:00
NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced the initiation of a Phase 2a clinical study to evaluate the safety and efficacy of PCN-101 (R-ketamine). R-ketamine is a stereoisomer of ketamine being developed for therapeutic treatment of psychiatric disorders such as Treatment Resistant Depression (TRD). The Phase 2a clinical trial has received the necessary regulatory and ethics approvals to initiate the study.
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression2021-09-09 16:30
BERLIN and SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its digital therapeutic platform Introspect Digital Therapeutics, Inc. (“Introspect”), today announced a usability study of Introspect's digital therapeutic (DTx) app technology in support of standard of care ketamine therapy for patients with treatment resistant depression (TRD) in collaboration with Kadima Neuropsychiatry. TRD impacts 100 million people globally, close to a third of the 300 million diagnosed with depression, many of whom are geographically restricted in their ability to access in-person psychological care.
The first state to legalize cannabis for medical use was California, in 1996. In 2001, medical marijuana was approved in Canada.
BERLIN, Sept. 03, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in in the following upcoming investor conferences in September: